OnKure's drug candidate pipeline is highlighted by OKI-219, a selective PI3K alpha H1047R inhibitor for the treatment of certain types of breast cancer that began clinical trials in February 2024.

PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; ...

PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 - ...

Merger and Financing – As previously announced, the merger between OnKure, Inc. and Reneo Pharmaceuticals ... Research and development (R&D) expenses were $14.4 million for the fourth quarter ...

Feb. 3, 2025 — Maternal vitamin D levels in the first trimester were related to both prenatal growth and pregnancy outcomes, according to a new study. Low vitamin D levels during the first ...

The sun is one of the best sources of vitamin D for the human body. How much sun a person needs per day depends on factors such as skin type, the season, and cloud coverage. Vitamin D is an ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...